Key facts
- Reunion Biotech’s last known valuation is $45.1M (Dec 2021).
- It has raised $35.4M; the latest was Later Stage VC ($14.5M) in Feb 2026.
- Notable investors include Qiming Venture Partners, Proxima Ventures (China), Yunfeng Capital, Qingdao Conson Financial Holdings, Dingxin Capital — 10 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 10 names
- ·Watchlist + deal alerts for Reunion Biotech
- ·The full record, as it builds
Funding rounds
No funding rounds for Reunion Biotech are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Reunion Biotech
Developer of medical hydrogel products intended to provide new medical solutions. The company provides clinical medical solutions such as tumor radiotherapy protection, wound repair, tumor embolism and innovative anti-tumor drugs, enabling clients with self-developed ready-to-use PEG hydrogel materials.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2018
- Website
- reunionbiotech.com/
- Ownership
- Privately Held (backing)
Reunion Biotech doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Reunion Biotech shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Reunion Biotech in its N-PORT filings yet. We sweep new filings monthly.